Neurodiagnostics Market Size and Growth 2025 to 2034
The global neurodiagnostics market size was valued at USD 19.35 billion in 2024 and is anticipated to reach around USD 26.28 billion by 2034, growing at a CAGR of 3.11% from 2025 to 2034. The neurodiagnostics market is expanding is driven by the factors such as the rising cases of neurological disorders such as Alzheimer’s and Parkinsons’s, continuous investments for developing advanced diagnostic tools, expanding healthcare infrastructure, and growing emphasis on personalized medicine.
Neurodiagnostics Market Key Takeaways
- North America dominated the market with a revenue share of 36% in 2024.
- Asia Pacific region is expected to grow at the fastest CAGR of 4.5% over the forecast period.
- The neuroimaging technologies segment dominated the neurodiagnostics market with a revenue share of over 58% in 2024.
- The in vitro diagnostics segment is expected to grow at the fastest CAGR of 4.2% over the forecast period.
- The hospitals and clinics segment dominated the market in 2023 with a revenue share of 43%.
- The imaging centers segment is to witness the fastest growth rate of 3.9% during the forecast period.
Market Overview
The neurodiagnostics market has evolved significantly over the past decade, becoming a vital component of neurological healthcare across the globe. Neurodiagnostics refers to a specialized branch of medical science dedicated to the assessment and interpretation of brain, spinal cord, and nerve activity using advanced diagnostic tools. These tools assist in identifying, monitoring, and managing neurological disorders such as epilepsy, Parkinson’s disease, Alzheimer’s, traumatic brain injury (TBI), stroke, multiple sclerosis, and brain tumors.
The growing incidence of neurological disorders—especially among aging populations—has significantly propelled demand for effective diagnostic solutions. As the global burden of dementia and neurodegenerative diseases rises, early detection becomes paramount for timely intervention and management. According to recent WHO estimates, over 55 million people live with dementia worldwide, with nearly 10 million new cases annually. This surge has directly influenced investments in neurodiagnostic technologies, aimed at providing insights into structural and functional abnormalities within the central and peripheral nervous systems.
A notable aspect of the neurodiagnostics market is its intersection with multiple technologies—ranging from neuroimaging (MRI, CT, PET, SPECT) to electrophysiology (EEG, MEG), and from molecular diagnostics to computational tools like neuroinformatics. This multidisciplinary nature has fostered rapid innovation and expanded the clinical utility of neurodiagnostic platforms beyond neurology departments—into intensive care units, research laboratories, sports medicine, and even military healthcare systems.
While historically centralized in tertiary hospitals, neurodiagnostic services are now accessible through diagnostic laboratories, outpatient imaging centers, and mobile health units. This decentralization, coupled with digitization and AI integration, is accelerating adoption across developed and emerging healthcare markets.
Major Trends in the Market
-
Rising Adoption of AI-Powered Imaging Platforms: Artificial intelligence is being integrated into neuroimaging tools for enhanced anomaly detection, image reconstruction, and predictive analytics.
-
Miniaturization of EEG & MEG Devices: Portable and wearable EEG/MEG devices are being increasingly used for home-based monitoring and long-term ambulatory diagnostics.
-
Shift Toward Preventive Neurology: Growing awareness about early neurological screening is driving proactive use of neurodiagnostic tools in at-risk populations.
-
Neuroinformatics Integration: The use of big data, machine learning, and bioinformatics to interpret complex brain data is redefining diagnosis workflows and outcomes.
-
Multimodal Imaging Synergies: There is a growing preference for combining MRI, PET, and MEG data to gain comprehensive anatomical and functional insights.
-
Point-of-Care Diagnostics Expansion: Point-of-care (POC) neurodiagnostic kits are seeing rapid development, especially for emergency stroke evaluation.
-
Rise in Pediatric Neurology Testing: Increasing cases of autism spectrum disorder (ASD), epilepsy, and developmental delays have pushed demand for child-friendly diagnostic tools.
-
Brain-Computer Interfaces (BCIs): Diagnostic capabilities are now influencing therapeutic domains, especially in rehabilitation using brain-computer interface technologies.
The immense potential of artificial intelligence (AI) is driving its implementation in neurodiagnostics workflows for enhancing the diagnostic accuracy and efficiency. AI algorithms can be applied in analysis of complex neuroimaging such as MRI and CT scans, and electroencephalogram (EEG) data, further enabling early disease detection for neurological disorders such as Alzheimer’s, stroke and brain tumors. Deployment of AI algorithms for EEG data interpretation, detection of seizure activity, or for classifying brain wave patterns associated with cognitive disorders is making diagnosis and prognosis more accessible for clinicians.
Biomarker discovery through analysis of large datasets with AI can potentially lead to development of novel diagnostic and therapeutic approaches. Furthermore, leveraging AI algorithms in neurosurgical planning such as for generating 3D brain models and simulating surgical scenarios can guide neurosurgeons in navigating delicate areas of the brain, leading to improved safety and accuracy during complex surgical procedures.
- For instance, in November 2024, Royal Philips, a globally leading company in health technology, announced the launch of its next-generation 1.5T BlueSeal MR wide-bore scanner at the RSNA 2024. The industry’s first-of-a-kind 70 cm wide-bore design, high-performance helium free 1.5T MR Smart Workflow solutions provides AI assistance at every step in the MRI workflow.
Neurodiagnostics Market Report Scope
Key Market Driver
The Rising Global Burden of Neurological Disorders
The most significant driver influencing the neurodiagnostics market is the increasing prevalence of neurological disorders. Age-related cognitive decline, the rise in lifestyle-related cerebrovascular diseases, and the growing cases of traumatic brain injury (TBI) due to road accidents or sports injuries are creating a strong demand for timely neurological assessment. For instance, Alzheimer's disease affects nearly 6.7 million Americans, with numbers expected to double by 2050.
These statistics emphasize the necessity for accurate, accessible, and early neurodiagnostic interventions. Disorders like epilepsy, which require electroencephalographic (EEG) monitoring, and multiple sclerosis, where MRI is a primary diagnostic modality, are becoming increasingly common in both developed and developing regions. Additionally, post-COVID-19 neurological syndromes have further highlighted the need for sophisticated diagnostic tools in the early detection and monitoring of neuroinflammation and related complications.
Key Market Restraint
High Cost and Limited Accessibility of Advanced Diagnostic Modalities
Despite technological advances, one of the major restraints limiting neurodiagnostic market expansion is the high cost of equipment and procedures. Devices like MRI, MEG, and PET scanners require significant capital investment, specialized personnel, and infrastructural support, making them accessible primarily to large hospitals or academic institutions. Furthermore, many of these devices require regular calibration and maintenance, adding to operational expenditures.
In low- and middle-income countries (LMICs), the availability of comprehensive neurodiagnostic setups remains sparse, creating disparities in neurological care. Insurance coverage for neurodiagnostic procedures also varies widely across geographies, adding to out-of-pocket patient burdens. This economic barrier inhibits broader adoption, especially in rural and under-resourced regions.
Key Market Opportunity
Integration of Tele-neurodiagnostics and Remote Monitoring
The rapid expansion of telemedicine offers an exciting opportunity for neurodiagnostics to reach underserved and remote populations. Tele-neurodiagnostics—enabled by wearable EEG devices, cloud-based image sharing, and remote analysis platforms—has the potential to overcome geographic and infrastructural limitations.
For instance, stroke patients in rural areas can now receive real-time diagnostic evaluations through teleradiology-supported CT/MRI scans, ensuring swift treatment decisions. Moreover, chronic neurological conditions like epilepsy or Parkinson’s disease can be monitored through ambulatory EEG systems, whose data is analyzed and reviewed remotely by specialists. This democratization of care, driven by digital technologies, can significantly expand the market's reach.
Technology Insights & Trends
Neuroimaging technologies have consistently held the dominant share in the neurodiagnostics market. MRI and CT scans are considered gold standards for structural brain imaging, offering high-resolution views of anatomical changes associated with tumors, hemorrhage, atrophy, and ischemic strokes. PET and SPECT imaging provide crucial insights into cerebral metabolism and perfusion patterns—vital for understanding dementia, seizure focus localization, and movement disorders. These modalities are well-integrated into clinical practice across hospitals and imaging centers, owing to their diagnostic precision and established reimbursement pathways.
On the other hand, Neuroinformatics is poised to be the fastest-growing segment, fueled by the explosion of brain-related data and the growing complexity of diagnostic needs. Neuroinformatics platforms use machine learning algorithms and bioinformatic tools to analyze multimodal brain imaging data, electrophysiology records, and genetic markers. These platforms are crucial in research-driven environments, enabling deeper insights into brain networks and disease progression models. Their utility in guiding precision medicine strategies is expected to elevate their role in both clinical and research settings.
Neurodiagnostics Market Size By Technology, 2024 to 2034 (USD Billion)
End Use Insights & Trends
Hospitals and clinics accounted for the largest end-use segment, given their comprehensive infrastructure and skilled workforce capable of operating complex neurodiagnostic equipment. These facilities typically house high-end MRI/PET/EEG units and have access to multidisciplinary teams for patient assessment and treatment. They are also the primary choice for acute neurological cases such as stroke, traumatic brain injury, or tumor management, where timely and integrated diagnostics are crucial.
Meanwhile, diagnostic laboratories are emerging as the fastest-growing end-user segment due to increased outsourcing of neurodiagnostic procedures and the rising demand for cost-effective outpatient services. Standalone imaging and electrophysiological labs offer specialized services like ambulatory EEG, evoked potential tests, and neuroimaging on a referral basis. These centers often provide quicker appointments, focused expertise, and lower costs, making them appealing to both patients and insurers. As healthcare systems move toward decentralization, the role of diagnostic labs in neurodiagnostics is set to expand significantly.
Neurodiagnostics Market Size By End Use , 2024 to 2034 (USD Billion)
Regional Insights & Trends
North America has established itself as the dominant region in the global neurodiagnostics market, driven by a highly advanced healthcare infrastructure, extensive insurance coverage, and a high prevalence of neurological conditions. The U.S. in particular, hosts a large number of academic medical centers, specialized neurology clinics, and well-equipped hospitals that utilize cutting-edge diagnostic platforms. Public initiatives like the BRAIN Initiative, and the presence of key industry players, have fostered substantial investments in research, device development, and AI integration into diagnostic workflows.
Furthermore, rising awareness campaigns, routine screening programs for cognitive decline, and strong telehealth networks contribute to North America's market leadership. The availability of skilled professionals and government support for neurodegenerative disease management also underpin the robust market ecosystem.
- For instance, in November 2024, Sense Neuro Diagnostics, a medical technology company, secured a $2 million contract for brain haemorrhage detection technology from the Department of Defense (DoD), Congressionally Directed Medical Research Programs (CDMRP) via the Traumatic Brain Injury and Psychological Health Research Program (TBI PHRP). The funding will clinical trials for the company’s NeuroHawk brain scanning device, which is designed for detecting haemorrhage in specific regions of the brain as well as for quick diagnosis of traumatic brain injury (TBI) in field conditions.
Asia-Pacific is witnessing the fastest growth in the neurodiagnostics market due to a combination of rising disease burden, improving healthcare access, and growing investments in diagnostic infrastructure. Countries like China and India are experiencing an increase in stroke incidence and age-related neurological conditions, prompting health systems to scale up diagnostic capacities. Government-backed insurance schemes and public-private partnerships are helping bridge the infrastructure gap.
Moreover, regional adoption of telemedicine and mobile diagnostic units is helping extend services to rural areas. Japan and South Korea, known for their advanced technology sectors, are actively incorporating neuroinformatics and AI into healthcare, while Southeast Asian nations are improving their tertiary care capacities. The region's large patient pool and under-penetrated diagnostic market make it an attractive area for expansion by global players.
Neurodiagnostics Market Size By Region, 2024 to 2034 (USD Billion)
Neurodiagnostics Market Top Key Companies:
- Canon Medical Systems Corporation
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Thermo Fisher Scientific, Inc.
- FUJIFILM Corporation
- Natus Medical Incorporated (Natus)
- Lifelines Neuro
- Advanced Brain Monitoring, Inc.
- NIHON KOHDEN CORPORATION.
- F. Hoffmann-La Roche Ltd
- GE HealthCare.
- Mitsar Co. LTD.
Recent Developments
- In May 2025, CND Life Scineces, Inc. (CND) successfully raised $13.5 million in its Series A equity financing round, which will be used for advancing innovation in neurodiagnostics. The company’s innovative Syn-One Test, utilizing skin biopsy tissue for detecting and quantifying the abnormal form of the alpha-synuclein protein, which is a well-known pathological biomarker of dementia with Lewy bodies (DLB), multiple system atrophy, Parkinson’s disease (PD) and other related disorders, is driving the company’s growth.
- In May 2025, Natus Medical Incorporated officially launched its highly anticipated point-of-care EEG solution, BrainWatch, which leverages the NeuroWorks platform and delivers the most complete ACNS-compliant rapid EEG solution in critical-care environments. The solution also offers an exclusive on-device software integrated with FDA-cleared Persyst algorithms for seizure detection and seizure burden.
- In April 2025, Cadwell Industries, the neurodiagnostics developer, introduced its newest Sierra software release, which will offer patent-pending, synchronized ultrasound and electromyography (EMG).
- In January 2025, AON Neurodiagnostics, Inc., a leading provider of neurodiagnostic care, declared its futuristic and impactful plans for transforming the In-Home Ambulatory Video EEG (AVEEG) services, which will improve patient access, enhance diagnostic accuracy, and streamline efficiency of operations, further breaking new ground for at-home neurodiagnostic testing.
Neurodiagnostics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Neurodiagnostics market.
By Technology
- Neuroimaging Technologies
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging (PET, SPECT)
- Near infrared spectroscopic imaging (NIRS)
- Electro-encephalography (EEG)
- Magneto-encephalography (MEG)
- Voxel based morphometry (VBM)
- In Vitro Diagnostics
- Neuroinformatics
By End Use
- Hospitals &s Clinics
- Diagnostic Laboratories
- Imaging Centers
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Request Customization
Get a Sample
Get a Sample
Request Customization